AI brief of an SEC Form 8-K · Mirum Pharmaceuticals, Inc. (MIRM)
Mirum says brelovitug met primary endpoint in Phase 3 AZURE-4 hepatitis delta study
Mirum Pharmaceuticals announced that brelovitug met the primary endpoint at Week 24 in the Phase 3 AZURE-4 study for chronic hepatitis delta virus. AZURE-4 is the second of two Phase 3 studies forming the basis of the company's planned U.S. registration package, and the company plans to submit a Biologics License Application to the FDA in the first half of 2027.
Key points
- At Week 24, 59% of patients on 300 mg weekly and 44% on 900 mg every four weeks met the combined virologic response and ALT normalization endpoint, versus 0% in the delayed-treatment arm (p≤0.0001).
- The study enrolled 113 treatment-naïve patients, 53% of whom had cirrhosis.
- Flu-like illness was the most common adverse event, reported in 17.2% (300 mg weekly) and 18.5% (900 mg every four weeks) of participants.
- A potential U.S. commercial launch is expected in the fourth quarter of 2027, if approved.
The filing
CompanyMirum Pharmaceuticals, Inc. (MIRM)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:41 AM ET
Accession number0001759425-26-000064
Written by AI on Nov 10, 2026, 7:50 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.